Vitamin K epoxide reductase (VKORC1) genetic polymorphism is associated to oral anticoagulant overdose

• References

• 1 Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention.. Am J Med 1993; 95: 315-28.
• 2 Verstuyft C, Robert A, Morin S. et al. Genetic and environmental risk factors for oral anticoagulant overdose.. Eur J Clin Pharmacol 2003; 58: 739-45.
• 3 Daly AK, King BP. Pharmacogenetics of oral anticoagulants.. Pharmacogenetics 2003; 13: 247-52.
• 4 Rost S, Fregin A, Ivaskevicius V. et. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.. Nature 2004; 427: 537-41.
• 5 Sadler JE. Medicine: K is for koagulation.. Nature 2004; 427: 493-4.
• 6 Li T, Chang CY, Jin DY. et al. Identification of the gene for vitamin K epoxide reductase.. Nature 2004; 427: 541-4.
• 7 Bodin L, Verstuyft C, Tregouet DA. et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.. Blood 2005; 106: 135-40.
• 8 D’Andrea G, D’Ambrosio RL, Di Perna P. et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.. Blood 2005; 105: 645-9.
• 9 Yuan HY, Chen JJ, Lee MT. et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.. Hum Mol Genet 2005; 14: 1745-51.
• 10 Rieder MJ, Reiner AP, Gage BF. et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.. N Engl J Med 2005; 352: 2285-93.